Tariq Shafi1, Philip G Zager2, Stephen M Sozio3, Morgan E Grams3, Bernard G Jaar4, Robert H Christenson5, L Ebony Boulware6, Rulan S Parekh7, Neil R Powe8, Josef Coresh9. 1. Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, MD. Electronic address: tshafi@jhmi.edu. 2. Division of Nephrology, University of New Mexico, Albuquerque, NM. 3. Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, MD. 4. Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, MD; Nephrology Center of Maryland, Baltimore, MD. 5. Department of Pathology, University of Maryland School of Medicine, Baltimore, MD. 6. Division of General Internal Medicine, Duke University School of Medicine, Chapel Hill, NC. 7. Department of Pediatrics, Hospital for Sick Children and Medicine, University Health Network, and University of Toronto, Toronto, Ontario, Canada. 8. Department of Medicine, San Francisco General Hospital and University of California, San Francisco, CA. 9. Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Epidemiology and Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
BACKGROUND: There is uncertainty regarding treatment of hypertension in hemodialysis patients due to the observed J-shaped association between blood pressure (BP) and death. We hypothesized that this association reflects confounding by cardiovascular disease (CVD) and that stratification by CVD biomarkers, cardiac troponin I (cTnI) and N-terminal fragment of prohormone brain natriuretic peptide (NT-proBNP), might change this association. STUDY DESIGN: National prospective cohort study. SETTING & PARTICIPANTS: 446 incident hemodialysis patients. PREDICTOR: Predialysis systolic BP. OUTCOMES: Mortality (all-cause and CVD) and first CVD event assessed using Cox regression adjusted for demographics, comorbid conditions, and clinical factors. MEASUREMENTS: Participants with cTnI level ≥0.1 ng/mL or NT-proBNP level ≥9,252 pg/mL were classified as the high-biomarker group; remaining participants were included in the low-biomarker group. RESULTS: Participants in the high-biomarker group (n=138 [31%]) were older (61 vs. 57 years) and had a higher prevalence of CVD (67% vs. 23%), but similar baseline BPs (152 vs. 153 mm Hg). There were 323 deaths (143 from CVD) and 271 CVD events. The high-biomarker group had a higher risk of mortality than the low-biomarker group (HR, 1.75; 95% CI, 1.37-2.24). The association between BP and outcomes differed between the 2 biomarker groups (P for interaction=0.01, 0.2, and 0.07 for all-cause mortality, CVD mortality, and first CVD event, respectively). In the low-biomarker group, BP was associated with greater risk of outcomes: HR per 10 mm Hg higher BP was 1.07 (95% CI, 1.01-1.14), 1.10 (95% CI, 0.96-1.25), and 1.04 (95% CI, 0.96-1.13) for all-cause mortality, CVD mortality, and first CVD event, respectively. Importantly, lower BP was not associated with increased risk of outcomes in stratified models, including for those in high biomarker group. LIMITATIONS: BP measurements not standardized. CONCLUSIONS: The observed J-shaped association between BP and outcomes in hemodialysis patients is due to confounding by subclinical CVD. A stratification approach based on cTnI and NT-proBNP levels has the potential to inform BP treatment in hemodialysis patients.
BACKGROUND: There is uncertainty regarding treatment of hypertension in hemodialysis patients due to the observed J-shaped association between blood pressure (BP) and death. We hypothesized that this association reflects confounding by cardiovascular disease (CVD) and that stratification by CVD biomarkers, cardiac troponin I (cTnI) and N-terminal fragment of prohormone brain natriuretic peptide (NT-proBNP), might change this association. STUDY DESIGN: National prospective cohort study. SETTING & PARTICIPANTS: 446 incident hemodialysis patients. PREDICTOR: Predialysis systolic BP. OUTCOMES: Mortality (all-cause and CVD) and first CVD event assessed using Cox regression adjusted for demographics, comorbid conditions, and clinical factors. MEASUREMENTS: Participants with cTnI level ≥0.1 ng/mL or NT-proBNP level ≥9,252 pg/mL were classified as the high-biomarker group; remaining participants were included in the low-biomarker group. RESULTS:Participants in the high-biomarker group (n=138 [31%]) were older (61 vs. 57 years) and had a higher prevalence of CVD (67% vs. 23%), but similar baseline BPs (152 vs. 153 mm Hg). There were 323 deaths (143 from CVD) and 271 CVD events. The high-biomarker group had a higher risk of mortality than the low-biomarker group (HR, 1.75; 95% CI, 1.37-2.24). The association between BP and outcomes differed between the 2 biomarker groups (P for interaction=0.01, 0.2, and 0.07 for all-cause mortality, CVD mortality, and first CVD event, respectively). In the low-biomarker group, BP was associated with greater risk of outcomes: HR per 10 mm Hg higher BP was 1.07 (95% CI, 1.01-1.14), 1.10 (95% CI, 0.96-1.25), and 1.04 (95% CI, 0.96-1.13) for all-cause mortality, CVD mortality, and first CVD event, respectively. Importantly, lower BP was not associated with increased risk of outcomes in stratified models, including for those in high biomarker group. LIMITATIONS: BP measurements not standardized. CONCLUSIONS: The observed J-shaped association between BP and outcomes in hemodialysis patients is due to confounding by subclinical CVD. A stratification approach based on cTnI and NT-proBNP levels has the potential to inform BP treatment in hemodialysis patients.
Authors: J Craig Longenecker; Michael J Klag; Santica M Marcovina; Yong-Mei Liu; Bernard G Jaar; Neil R Powe; Nancy E Fink; Andrew S Levey; Josef Coresh Journal: J Am Soc Nephrol Date: 2005-03-30 Impact factor: 10.121
Authors: Mahboob Rahman; Valerie Griffin; Arun Kumar; Fauzia Manzoor; Jackson T Wright; Michael C Smith Journal: Am J Kidney Dis Date: 2002-06 Impact factor: 8.860
Authors: Kamyar Kalantar-Zadeh; Ryan D Kilpatrick; Charles J McAllister; Sander Greenland; Joel D Kopple Journal: Hypertension Date: 2005-02-07 Impact factor: 10.190
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Rajiv Agarwal; Allen R Nissenson; Daniel Batlle; Daniel W Coyne; J Richard Trout; David G Warnock Journal: Am J Med Date: 2003-09 Impact factor: 4.965
Authors: M J Klag; P K Whelton; B L Randall; J D Neaton; F L Brancati; C E Ford; N B Shulman; J Stamler Journal: N Engl J Med Date: 1996-01-04 Impact factor: 91.245
Authors: Julia J Scialla; Rulan S Parekh; Joseph A Eustace; Brad C Astor; Laura Plantinga; Bernard G Jaar; Tariq Shafi; Josef Coresh; Neil R Powe; Michal L Melamed Journal: Am J Nephrol Date: 2015-08-20 Impact factor: 3.754
Authors: Nisha Bansal; Charles E McCulloch; Feng Lin; Arnold Alper; Amanda H Anderson; Magda Cuevas; Alan S Go; Radhakrishna Kallem; John W Kusek; Claudia M Lora; Eva Lustigova; Akinlolu Ojo; Mahboob Rahman; Cassianne Robinson-Cohen; Raymond R Townsend; Jackson Wright; Dawei Xie; Chi-Yuan Hsu Journal: Hypertension Date: 2017-07-03 Impact factor: 10.190
Authors: Tariq Shafi; Stephen M Sozio; Jason Luly; Karen J Bandeen-Roche; Wendy L St Peter; Patti L Ephraim; Aidan McDermott; Charles A Herzog; Deidra C Crews; Julia J Scialla; Navdeep Tangri; Dana C Miskulin; Wieneke M Michels; Bernard G Jaar; Philip G Zager; Klemens B Meyer; Albert W Wu; L Ebony Boulware Journal: Medicine (Baltimore) Date: 2017-02 Impact factor: 1.889